Digoxin

CAS No:
20830-75-5 Category:
  • #LGM Pharma is a Digoxin CAS# 20830-75-5 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 20830-75-5
  • AHFC code: 24:04.08 80:04.00
  • Synonyms: Digitalis Glycoside
  • ATC Code: C01AA02 C01AA05 C01AA08 V03AB24
  • Chemical Formula: C24H30O3
  • Molecular Weight: 780.9385
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00390 (APRD00098)
  • SMILES: [H][C,]12CC[C,]3([H])[C,]([H])(C[C,,H](O)[C,]4(C)[C,H](CC[C,]34O)C3=CC(=O)OC3)[C,,]1(C)CC[C,,H](C2)O[C,H]1C[C,H](O)[C,H](O[C,H]2C[C,H](O)[C,H](O[C,H]3C[C,H](O)[C,H](O)[C,,H](C)O3)[C,,H](C)O2)[C,,H](C)O1
  • InChl: LTMHDMANZUZIPE-PUGKRICDSA-N
  • PubChem: 30322
  • IUPAC:

Additional Details

Indication:
For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
Pharmacodynamics:
Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mode of Action:
Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX)in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Metabolism:
Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.
Toxicity:
Toxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
General Reference:
Thompson DF, Carter JR: Drug-induced gynecomastia. Pharmacotherapy. 1993 Jan-Feb;13(1):37-45. Pubmed Doering W, Konig E, Sturm W: [Digitalis intoxication: specifity and significance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (authorês transl)] Z Kardiol. 1977 Mar;66(3):121-8. Pubmed Kaplanski J, Weinhouse E, Topaz M, Genchik G: Verapamil and digoxin: interactions in the rat. Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):377-88. Pubmed Flanagan RJ, Jones AL: Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos